Solid compositions containing polyethylene oxide and an active ingredient
AssigneePharma Pass LLC
InventorsPawan Seth, Andre Stamm
Life of this patent
Estimating the term…
Abstract
A solid composition is disclosed comprising an active ingredient that is not in amorphous form in association with polyethylene oxide and conventional additives, excluding basic compounds. Such compositions are suitable for use as pharmaceutical compositions. A method for their preparation is also disclosed.
Claims24
A solid pharmaceutical composition comprising, by weight based on the total weight of the composition:
- (a) from 5 to 45% of an active ingredient which is not in an amorphous form selected from the group consisting of acyclovir, nifedipine, nicardipine, captopril, verapamil, diltiazem, oxybutynine, valacyclovir, glipizide, felodipine, isosorbide, carbidopa, levodopa and pentoxiphylline;
- (b) from 25 to 70% polyethylene oxide;
- (c) the balance consisting of conventional additives, excluding basic components,
- said composition being obtained by the process, comprising the steps consisting of:
- (i) mixing in the dry state and for a sufficient time, an active ingredient, polyethylene oxide and optionally, one or several additives;
- (ii) adding solvent, followed by mixing for a sufficient period of time;
- (iii) granulation;
- (iv) drying the granules thus formed for a sufficient period of time;
- (v) optionally adding one or more additives, with mixing in the dry state for a sufficient time and passage through a suitable sieve;
- (vi) optionally adding one or several additives and mixing in the dry state for a sufficient period of time;
- (vii) compressing the mixture obtained from the preceding steps to obtain the desired compressed tablet;
- and
- (viii) optionally coating said compressed tablet.
A solid pharmaceutical composition comprising, by weight based on the total weight of the composition:
- (a) from 5 to 45% of nifedipine which is not in an amorphous form;
- (b) from 25 to 70% polyethylene oxide;
- (c) the balance consisting of conventional additives, excluding basic components,
- said composition being obtained by the process, comprising the steps consisting of:
- (i) mixing in the dry state and for a sufficient time, an active ingredient, polyethylene oxide and optionally, one or several additives;
- (ii) adding alcohol, followed by mixing for a sufficient period of time;
- (iii) granulation by passage through a suitable sieve;
- (iv) drying the granules thus formed for a sufficient period of time;
- (v) optionally adding one or more additives, with mixing in the dry state for a sufficient time and passage through a suitable sieve;
- (vi) optionally adding one or several additives and mixing in the dry state for a sufficient period of time;
- (vii) compressing the mixture obtained from the preceding steps to obtain the desired compressed tablet;
- and
- (viii) optionally coating said compressed tablet.
A solid pharmaceutical composition comprising, by weight based on the total weight of the composition:
- (a) from 5 to 45% of glipizide which is not in an amorphous form;
- (b) from 25 to 70% polyethylene oxide;
- (c) the balance consisting of conventional additives, excluding basic components,
- said composition being obtained by the process, comprising the steps consisting of:
- (i) mixing in the dry state and for a sufficient time, an active ingredient, polyethylene oxide and optionally, one or several additives;
- (ii) adding alcohol, followed by mixing for a sufficient period of time;
- (iii) granulation by passage through a suitable sieve;
- (iv) drying the granules thus formed for a sufficient period of time;
- (v) optionally adding one or more additives, with mixing in the dry state for a sufficient time and passage through a suitable sieve;
- (vi) optionally adding one or several additives and mixing in the dry state for a sufficient period of time;
- (vii) compressing the mixture obtained from the preceding steps to obtain the desired compressed tablet;
- and
- (viii) optionally coating said compressed tablet.
A solid pharmaceutical composition comprising, by weight based on the total weight of the composition:
- (a) from 5 to 45% of oxybutynine which is not in an amorphous form;
- (b) from 25 to 70% polyethylene oxide;
- (c) the balance consisting of conventional additives, excluding basic components,
- said composition being obtained by the process, comprising the steps consisting of:
- (i) mixing in the dry state and for a sufficient time, an active ingredient, polyethylene oxide and optionally, one or several additives;
- (ii) adding alcohol, followed by mixing for a sufficient period of time;
- (iii) granulation by passage through a suitable sieve;
- (iv) drying the granules thus formed for a sufficient period of time;
- (v) optionally adding one or more additives, with mixing in the dry state for a sufficient time and passage through a suitable sieve;
- (vi) optionally adding one or several additives and mixing in the dry state for a sufficient period of time;
- (vii) compressing the mixture obtained from the preceding steps to obtain the desired compressed tablet;
- and
- (viii) optionally coating said compressed tablet.
A solid pharmaceutical composition comprising, by weight based on the total weight of the composition:
- (a) from 5 to 45% of felodipine which is not in an amorphous form;
- (b) from 25 to 70% polyethylene oxide;
- (c) the balance consisting of conventional additives, excluding basic components,
- said composition being obtained by the process, comprising the steps consisting of:
- (i) mixing in the dry state and for a sufficient time, an active ingredient, polyethylene oxide and optionally, one or several additives;
- (ii) adding alcohol, followed by mixing for a sufficient period of time;
- (iii) granulation by passage through a suitable sieve;
- (iv) drying the granules thus formed for a sufficient period of time;
- (v) optionally adding one or more additives, with mixing in the dry state for a sufficient time and passage through a suitable sieve;
- (vi) optionally adding one or several additives and mixing in the dry state for a sufficient period of time;
- (vii) compressing the mixture obtained from the preceding steps to obtain the desired compressed tablet;
- and
- (viii) optionally coating said compressed tablet.
Dependencies are inferred from the claim text.